ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 83 filers reported holding ACLARIS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.08 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,378,446 | -37.0% | 201,233 | -4.6% | 0.01% | -36.4% |
| Q2 2023 | $2,186,380 | +53.0% | 210,837 | +19.4% | 0.01% | +37.5% |
| Q1 2023 | $1,429,099 | +438.6% | 176,650 | +948.6% | 0.01% | +300.0% |
| Q4 2022 | $265,325 | -37.3% | 16,846 | -37.3% | 0.00% | -33.3% |
| Q3 2022 | $423,000 | +422.2% | 26,854 | -15.0% | 0.00% | +200.0% |
| Q3 2020 | $81,000 | – | 31,575 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |